IL2 and cancer: Furthermore, the combination approach triggered delayed hypersensitivity reactions, which were associated with enhanced activation of lymphocytes and tumor cell destruction, highlighting the synergistic benefits of liposomal IL-2 in cancer immunotherapy [25].